The Small Molecule Screening and Synthesis Facility (SMSSF) fosters collaborative drug discovery research between chemists, biologists and physician scientists that leads to the identification of new small molecules that inhibit disease targets and phenotypes in biochemical and cellular models relevant to any therapeutic area.
Our drug discovery services include:
News and Accomplishments
Scott Wildman, PhD has recently joined the Small Molecule Screening Facility. Scott is a computational chemist with expertise in drug design, molecular modeling, virtual screening and HTS hit triage. He will be collaborating with investigators from across campus to identify and optimize the design of small molecules and peptides that interact with targets of therapeutic and biological interest. Scott comes to UW from Washington University in St. Louis where he was a Research Assistant Professor in the Department of Biochemistry and Molecular Biophysics, and the Scientific Director of both the High-throughput Screening Core and Peptide Synthesis Core. Prior to that, he worked at Pfizer for 7 years on a wide variety of drug targets, moving two molecules into clinical trials. He has a PhD in Medicinal Chemistry from the University of Michigan.
Tip-less, acoustic liquid dispensing of aqueous and DMSO solutions in 2.5nanoliter(!) and up volumes into 96, 384 and 1536-well plates is now available for any application on an Echo 555.
View the Small Molecule Screening and Synthesis Facility's Scientific Accomplishments.
Funding received from the UWCCC Cancer Center Support Grant (CCSG) for published research, including the use of UWCCC Shared Resources to generate or analyze data, or conduct clinical trials, needs to reference the UWCCC. See Acknowledging UWCCC in Publications, Posters and Presentations.
View the UW Drug Discovery and Development website for more information on other UW-Madison laboratory facilities that provide state-of-the-art instrumentation and expert scientific staff.